1. Home
  2. LNTH vs PRAX Comparison

LNTH vs PRAX Comparison

Compare LNTH & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantheus Holdings Inc.

LNTH

Lantheus Holdings Inc.

N/A

Current Price

$101.08

Market Cap

6.5B

Sector

Health Care

ML Signal

N/A

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

N/A

Current Price

$322.99

Market Cap

7.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LNTH
PRAX
Founded
1956
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
7.1B
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
LNTH
PRAX
Price
$101.08
$322.99
Analyst Decision
Hold
Strong Buy
Analyst Count
10
21
Target Price
$106.99
★ $650.00
AVG Volume (30 Days)
★ 1.1M
420.7K
Earning Date
11-05-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ 3.21
N/A
Revenue
★ $343,374,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$12.85
$41,442.59
P/E Ratio
$31.36
★ N/A
Revenue Growth
★ 3.62
N/A
52 Week Low
$50.69
$160.11
52 Week High
$111.86
$392.70

Technical Indicators

Market Signals
Indicator
LNTH
PRAX
Relative Strength Index (RSI) 61.26 63.91
Support Level $99.84 $307.93
Resistance Level $101.24 $347.63
Average True Range (ATR) 0.43 16.67
MACD 0.11 5.68
Stochastic Oscillator 88.82 96.95

Price Performance

Historical Comparison
LNTH
PRAX

About LNTH Lantheus Holdings Inc.

Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: